AZD4573 是一种有效的选择性 CDK9 抑制剂，IC50值小于 4 nM，可以用于治疗血液系统恶性肿瘤的研究。

AZD4573 is an effective and selective CDK9 inhibitor (IC50:<4 nM). It enables transient target engagement for the treatment of hematologic malignancies.

Short-term treatment with AZD4573 led to a rapid dose- and time-dependent decrease in cellular pSer2-RNAPII, resulting in activation of caspase 3 and cell apoptosis in a broad range of hematological cancer cell lines (e.g. caspase activation EC50 13.7 nM in an acute myeloid leukemia model MV4-11).

AZD4573 exhibits a short half-life in multiple species (less than one hour in dog, rat, and monkey) and good solubility for intravenous administration.

2057509-72-3

C22H28ClN5O2

429.94

DMSO:125 mg/mL (290.74 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years